Mission Wealth Management LP Sells 1,804 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mission Wealth Management LP lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 77.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 532 shares of the biopharmaceutical company’s stock after selling 1,804 shares during the quarter. Mission Wealth Management LP’s holdings in Regeneron Pharmaceuticals were worth $379,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Private Wealth Management Group LLC increased its stake in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. Truvestments Capital LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at $49,000. Institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

REGN has been the subject of a number of recent research reports. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Bernstein Bank decreased their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target for the company. Finally, TD Cowen decreased their price target on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $687.15 on Thursday. The company’s 50-day moving average is $696.58 and its 200 day moving average is $857.92. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market capitalization of $75.12 billion, a P/E ratio of 17.95, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $642.00 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.